Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

VAPERACE

Led by Naomi Hamburg, the Joseph A. Vita, MD Professor at the Boston University School of Medicine, this team will establish the Rapidly Advancing Discovery to Arrest the Outbreak of Youth Vaping Center and will include four intersecting projects at Boston University, Johns Hopkins University, Stanford University and the University of Louisville.

These projects include: basic research using human induced pluripotent stem cell samples to test the toxicity of the components of e-cigarettes; mobile health technology to measure the physiological cardiovascular impacts of e-cigarettes on youth in real-world settings and a virtual reality and text messaging delivered e-cigarette cessation program for youth developed by combining social media methods with focus groups.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login